Acute Erythroid Leukemia

Watchlist

(log in to enable)

Retrieved

2021-01-23

Source

Orphanet

Trials

—

Genes

EPOR, CAD, DHODH, UMPS, GATA1, FLII, FLI1, HBB, HBG2, JAK2, HBG1, ERBB2, EPO, SPI1, TP53, FANCB, RAB8A, NFE2, STAT3, EGFR, DNASE1, KIT, TAL1, GYPA, HBA1, HBA2, ERBB3, TGFB1, TFRC, ABCB1

EPOR, CAD, DHODH, UMPS, GATA1, FLII, FLI1, HBB, HBG2, JAK2, HBG1, ERBB2, EPO, SPI1, TP53, FANCB, RAB8A, NFE2, STAT3, EGFR, DNASE1, KIT, TAL1, GYPA, HBA1, HBA2, ERBB3, TGFB1, TFRC, ABCB1, ABL1, HBE1, HBB-LCR, HSPA4, NRG1, ACTB, NPTN, ERBB4, NOTCH1, SCLY, GYPE, GYPB, IL6, TNF, HSF2, CSF2, KRT7, GFI1B, AQP1, TGM2, ERVK-20, ITGA2B, STAT5B, KDM1A, NRAS, TBXA2R, ABCB6, GLB1, NME1, ALAS2, STAT5A, BCL2, TGFBI, RUNX1, GAB1, PPARG, ERVW-1, CR1, PTGS2, CTNNB1, RELA, CEBPA, HEMGN, SRGN, WT1, MINDY4, PF4, ERVK-32, SPTAN1, TH, THRA, TIMP1, RPS6KB2, MIR486-1, RNASE3, TPI1, MIR17HG, SYT1, RARG, MIR23A, VEGFA, SRI, WRN, SSTR4, SETMAR, SPIB, SLC22A1, TFCP2, SLC4A1, TBXAS1, SKP2, PRDX2, SIX1, SHMT2, TF, TFF3, YWHAE, TFPI, TFR2, COMMD3-BMI1, STAT1, CD24, TGFB2, POTEF, ERVK-18, GORASP1, CNBP, ZNF148, STK38, RASA3, PEG10, PDIK1L, TBC1D9, ACSL6, PTPMT1, SF3B1, ZMYND8, VENTX, EML4, TRIB2, UBASH3B, SLC25A18, CENPU, CYP2S1, ACSL5, DERL1, CMPK1, TET2, UCKL1, SLC12A9, ACKR3, WNK1, MTUS1, ZNF410, ERVK-6, ZFPM1, WWP1, PRDX3, ATG5, CXCR4, HBFQTL2, MAFK, BECN1, S1PR4, HCAR3, GINGF2, TRPA1, CLDN10, PDCD5, LPAR2, LONP1, ATP6AP2, NUDC, PIAS3, PRMT5, CARM1, MIR152, RAF1, ATG7, MIR125A, MIRLET7C, RTL1, ASXL1, HEXIM1, CXCR6, RARA, P4HB, RAB2A, EZH2, E2F1, E2F4, E2F6, EDNRA, EGR1, ELF4, EPAS1, EPHB2, ERG, ESR1, ETS1, ETS2, ETV6, FDXR, HLA-G, FECH, FLT3, FLT4, FUT8, G6PD, GATA2, GFI1, GP1BA, GPR42, GSTP1, HBD, HBQ1, HBZ, DMD, DKC1, CYLC2, CYLC1, PARP1, ADRA1A, ADRA2B, AGT, AKR1B1, ALK, ALOX12, ANXA4, ANXA6, BAX, BCR, BMI1, BRS3, BTK, CALCR, CASP1, CASP3, CD19, TNFRSF8, CD34, CD44, CDKN1A, CDX4, CNP, COL11A2, CPOX, CSF1R, CFHR1, HMOX2, NECTIN1, PCNA, MPL, ABCC1, MTTP, MYB, MYC, NFE2L2, NONO, NPM1, NTRK1, P2RY6, PAFAH1B1, PAX2, PBX2, PDGFB, HNRNPA1, PIK3CA, PIK3CB, PIM1, PIK3CD, PIK3CG, PLAT, PML, POU2F1, MAPK1, MAPK3, MAPK8, PSMC5, PTH, NR3C2, KMT2A, MLF1, CXCL9, HOXC5, HOXD3, HRAS, PRMT1, HSF1, HSP90AA1, HSPG2, ID3, IDH2, IDUA, IL3, IL5, IL5RA, IL11, ILF3, INHBA, INPPL1, JAK1, JAK3, STMN1, LPA, LYL1, SMAD7, MAG, MCL1, ME2, MEFV, LOC110011217

Drugs

(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl) amino)methyl)tetrahydrofuran-3,4-diol, (S)-5-(1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethylamino-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile, 1,2-bis(methylsulphonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine, 1-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-3-(3-fluorophenyl)urea, 1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, 1-[2-(Benzo[1,2,5]thiadiazol-5-ylamino)-6-(2,6-dichloro-phenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3- tert-butyl-urea, 2-((3-((4-((3-aminopropyl)amino)butyl)amino)propyl)amino)-N-((5S,5aS,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl)acetamide, tetrahydrochloride, 2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thienol[3,2,-f]-[1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)-acetamide dihydrate, 2-[[3-({4-[(5-{2-[(3-Fluorophenyl)amino]-2-oxoethyl}- 1H-pyrazol-3-yl)amino]- quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate trihydrate, 2-hydroxymethyl-2-methoxymethyl-1-azabicyclo[2,2,2]octan-3-one, 225Ac-lintuzumab, 26 base single stranded phosphodiester DNA oligonucleotide, 5'-O-(trans-9"-octadecenoyl)-1-ß-D-arabinofuranosyl cytosine, 6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one monocitrate, Allogeneic T cells encoding an exogenous TK gene, Allogeneic bone marrow stem cells treated ex vivo with 16,16-dimethyl prostaglandin E2, Allogeneic ex vivo expanded umbilical cord blood cells, Allogeneic ex vivo-generated natural killer cells from CD34+ umbilical cord blood progenitor cells, Allogeneic human dendritic cells derived from a CD34+ progenitor cell line, Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus, Allogeneic umbilical cord blood cells treated ex vivo with 16,16-dimethyl prostaglandin E2, Allogeneic, umbilical cord blood-derived, ex vivo-expanded, haematopoietic CD133+ cells / allogeneic, umbilical cord blood-derived, non-expanded, haematopoietic CD133- cells, Alvocidib, Amonafide L-malate, Antisense oligonucleotide 5'-d[P-Thio} (CCCTG CTCCC CCCTG GCTCC)-3', Arsenic trioxide ( Arsenic Trioxide Accord, Arsenic trioxide Mylan, Arsenic trioxide medac, TRISENOX ), Azacitidine ( AZACITIDINE ACCORD, AZACITIDINE BETAPHARM, AZACITIDINE CELGENE, AZACITIDINE MYLAN, VIDAZA ), Bisantrene hydrochloride, Clofarabine ( CLOLAR, EVOLTRA, IVOZALL ), Combretastatin A1 diphosphate-, Crenolanib besylate, Daunorubicin (liposomal), Decitabine ( DACOGEN ), Devimistat, Donor lymphocyte preparation depleted of functional alloreactive T-cells, Enasidenib ( IDHIFA ), Entospletinib, Eryaspase ( GRASPA ), Fully human IgG1 antibody specific for CD33, Gemtuzumab Ozogamicin ( MYLOTARG ), Gilteritinib ( XOSPATA ), Glasdegib ( DAURISMO ), Guadecitabine, Histamine dihydrochloride ( CEPLENE ), Homoharringtonine ( CEFLATONIN ), Human monoclonal antibody against inhibitory killer cell lg-like receptors (1-7 F9), Idasanutlin, Inecalcitol, Isocitrate dehydrogenase 2-mutant inhibitor, Ivosidenib ( TIBSOVO ), L-Asparaginase ( KIDROLASE, SPECTRILA ), Laromustine ( CLORETATZNE ), Lestaurtinib, Lintuzumab, Liposomal combination of cytarabine and daunorubicin ( VYXEOS ), Liposomal daunorubicin, Midostaurin ( RYDAPT ), Mitoxantrone ( NOVANTRONE ), N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide, N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-(morpholin-4-yl)ethoxy)imidazo[2,1- b][1,3]benzothiazol-2-yl]phenyl}urea di-hydrochloride salt, N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide hydrochloride, NEDD8-activating enzyme (NAE) inhibitor, Onvansertib, P-ethoxy growth factor receptor-bound protein 2 (Grb2) antisense oligonucleotide, Plerixafor ( MOZOBIL ), Pracinostat, Recombinant human histone H1.3 and recombinant human N-bis-met-histone H1.3, Recombinant human interleukin-3 truncated diphtheria toxin fusion protein ( ELZONRIS ), Ribonucleotide reductase R2 specific phosphorothioate oligonucleotide, Sapacitabine, Selinexor ( XPOVIO ), Tamibarotene, Tipifarnib ( ZARNESTRA ), Tosedostat, Troxacitabine, Ulocuplumab, Vadastuximab talirine, Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptide, sequence 169-177, of proteinase 3), Venetoclax ( VENCLEXTA, VENCLYXTO ), Volasertib, Vosaroxin, Wilms' tumour 1 (WT1) vaccine, Zosuquidar trihydrochloride, cenisertib, cusatuzumab, haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate, humanised monoclonal antibody of the IgG4 kappa isotype targeting CD47, lysine-specific histone demethylase (LSD1, also known as KDM1A) inhibitor

Interested in hearing about new therapies?

A rare unclassified acute myeloid leukemia characterized by a proliferation of immature cells exclusively of the erythroid lineage without a significant myeloblastic component. Microscopically, the cells may be undifferentiated or proerythroblastic in appearance. Patients may present with pancytopenia with fatigue, infections, and mucocutaneous bleedings, as well as weight loss, fever, and night sweats. Prognosis is poor.